The effect of memantine on post-ECT cognition in depressed elderly

Effect of memantine on cognitive impairments after ECT in elderly with major depressive disorder: a randomized double-blind placebo-controlled clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20151122025191N2

Enrollment

Registered

2020-09-17

Start date

2020-10-22

Completion date

Unknown

Last updated

2020-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder. Major depressive disorder, single episode

Interventions

Intervention 1: Intervention group: From the day before the ECT sessions, the patient will receive 10mg/day Memantine tablet, which will continue until the last ECT session. Each patient will take bet

Eligibility

Sex/Gender

All

Age

60 Years to No maximum

Inclusion criteria

Inclusion criteria: Diagnosis of Major Depressive Disorder Clinical Indication for Electroconvulsive Therapy

Exclusion criteria

Exclusion criteria: Diagnosis of Dementia Diagnosis of Delirium Hx of Major Axis I disorder(Schizophrenia, Schizoaffective, Bipolar I,II ) Medical contraindication

Design outcomes

Primary

Measure	Time frame
Addenbrooke's Cognitive Examination Score. Timepoint: before and 24 hour after electroconvulsive treatment. Method of measurement: Addenbrooke's Cognitive Examination-II Score.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBehnam Shariati

Iran University of Medical Sciences

behnamshariatimd@gmail.com+98 21 6655 1655

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026